FDA's One-Day Inspectional Assessment Pilot: What Wholesale Drug Distributors Need to Know

The FDA launched a pilot program in February 2025 allowing certain drug facilities to undergo one-day inspectional assessments instead of traditional multi-day inspections. Wholesale drug distributors and third-party logistics providers operating under 21 CFR Part 205 and 21 CFR Part 211 may qualify if they meet narrow eligibility criteria tied to compliance history and facility complexity.

Regulatory Background

FDA facility inspections of wholesale drug distributors are conducted under authority of the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 704. Traditional inspections typically span 2-5 days depending on facility size, product scope, and operational complexity. The Drug Quality and Security Act (DQSA) of 2013, which established the Drug Supply Chain Security Act (DSCSA), expanded FDA's inspection scope to include verification of transaction documentation, product tracing systems, and trading partner verification protocols.

Under 21 CFR 205.50, wholesale distributors must maintain records and permit FDA access during reasonable business hours. The new pilot program does not alter these statutory requirements — it modifies the inspection execution model for facilities meeting specific pre-qualification criteria.

Pilot Program Details

The One-Day Inspectional Assessment applies only to facilities that:

1. Have undergone at least two prior FDA inspections with no Form 483 observations in the most recent inspection
2. Operate a single-site facility with fewer than 50,000 square feet of controlled storage space
3. Handle prescription drugs only — no biologics, controlled substances requiring DEA oversight, or compounded preparations
4. Maintain current FDA registration under 21 CFR 207.21 and state wholesale drug distributor licensure in all jurisdictions where they operate
5. Have submitted a voluntary request to participate in the pilot by completing FDA Form 3731-OD (released January 2025)

The one-day assessment focuses on four compliance areas: storage and handling documentation (temperature logs, deviation reports), transaction history verification under DSCSA, product returns and destruction procedures, and personnel training records. FDA investigators will not conduct full cGMP assessments during these shortened inspections. Facilities that receive any Form 483 observations during a one-day assessment revert to standard multi-day inspection protocols for subsequent visits.

The pilot runs through September 2026. FDA's Office of Regulatory Affairs will evaluate whether shortened inspections maintain equivalent compliance oversight compared to traditional inspection models.

Operational Impact

Wholesale distributors considering participation must assess whether a one-day inspection aligns with their pharmaceutical inspection readiness posture. Facilities that qualify are typically small-scale operations with straightforward product handling — regional distributors serving local pharmacy networks, specialized 3PLs handling single therapeutic categories, or reverse distributors managing prescription drug returns.

The operational advantage is clear: reduced inspection duration means less disruption to daily operations. However, the condensed timeframe requires precise documentation organization. FDA investigators will expect immediate access to transaction records, temperature monitoring data, and training documentation without time for retrieval or assembly. Facilities accustomed to multi-day inspections, where Day 1 often includes orientation and initial document requests, must adjust to a model where all materials are inspection-ready at 8:00 AM on the single inspection day.

For 3PLs operating multiple client contracts under one facility license, the pilot presents coordination challenges. FDA investigators will randomly select products and transactions for review during the one-day assessment. If those selections span multiple clients, the facility must produce documentation across all client systems within the compressed timeframe. Multi-client operations may find standard inspections preferable despite longer duration.

The pilot does not reduce compliance obligations. A wholesale drug distributor audit under this program applies identical regulatory standards as traditional inspections. The difference is execution time, not regulatory scope.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — the baseline requirement for pilot program eligibility. However, the pilot's narrow criteria suggest only a small subset qualifies. The average compliance score across all tracked entities is 51/100, placing most distributors in the "Fair" tier (919 entities). This tier typically reflects facilities with active state licensure and FDA registration but limited visibility into NABP accreditation or clean inspection history.

Only 28 entities in the directory currently hold "Excellent" scores (75-100 points), which correlate with verified NABP accreditation, multi-state licensure, and no enforcement actions on record. These high-scoring entities are the most likely candidates for one-day assessments, assuming they meet the facility size and product scope restrictions. The 73 entities with FDA recalls on record are automatically disqualified — the pilot requires clean compliance histories.

The compliance score distribution reveals a structural challenge: pharmaceutical distributor compliance visibility is limited for most entities. Only 63 tracked distributors hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation, a voluntary third-party verification that signals strong cGMP adherence and inspection readiness. Facilities without VAWD or equivalent accreditation may struggle to demonstrate the compliance posture FDA expects for shortened inspections.

Practical Guidance for Compliance Officers

• Check FDA registration status immediately: Use ColdChainCheck's directory to verify that your facility and any 3PL partners hold current FDA registration. Filter by "FDA Registration" under compliance signals. Expired or pending registrations disqualify entities from the pilot and indicate broader compliance gaps.

• Request prior inspection reports from trading partners: If you rely on third-party logistics providers, confirm they have clean Form 483 histories from the past two inspection cycles. ColdChainCheck tracks enforcement actions, but not all Form 483s result in public enforcement. Request copies directly from 3PLs during vendor qualification reviews.

• Evaluate facility size against the 50,000 sq ft threshold: The pilot excludes large distribution centers. If your primary 3PL operates a regional hub exceeding this limit, they will not qualify regardless of compliance history. Smaller, specialized cold chain providers handling single therapeutic categories are better candidates.

• Monitor DSCSA transaction documentation systems: The one-day assessment prioritizes transaction history verification. Ensure your ATP/VRS systems can produce serialized product transaction data within minutes, not hours. FDA investigators will not wait while IT teams pull archived records.

For ongoing tracking of FDA enforcement actions and wholesale drug distributor audit outcomes, see ColdChainCheck's wholesale distributor compliance guide. The directory updates monthly as new state licensure and FDA registration data becomes available.

Disclaimer: This article provides informational content based on publicly available FDA guidance and is not legal or regulatory advice. Wholesale drug distributors should consult qualified regulatory counsel and verify all compliance requirements with the FDA and relevant state boards of pharmacy.